{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-122758","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2021-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.895550+00:00","generated_at":"2026-06-28T23:02:45.141074+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elanco to carve out microbiome R&D platform; appoints new innovation chief","bullets":["Ellen de Brabander, Ph.D., named EVP of Innovation and Regulatory Affairs, effective Oct 18, 2021.","Aaron Schacht will lead the carve-out of Elanco's microbiome R&D platform into an independent biopharma company.","Carve-out expected by Q1 2022; Elanco may retain minority stake; J.P. Morgan advising.","Elanco reaffirms 2025 innovation revenue target of $600–700M, supported by KindredBio acquisition and pipeline.","Pet health portfolio increased as a percentage of pipeline; focus on high-value late-stage candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-122758","json":"https://secwatch.observer/filing/0001104659-21-122758.json","markdown":"https://secwatch.observer/filing/0001104659-21-122758.md","text":"https://secwatch.observer/filing/0001104659-21-122758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000110465921122758/0001104659-21-122758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000110465921122758/tm2129160d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T23:02:45.141074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88da2b4176","claim":"Aaron Schacht changed role as Executive Vice President of Innovation, Regulatory, and Business Development at Elanco Animal Health Inc.","evidence_excerpt":"Aaron Schacht, Elanco’s Executive Vice President of Innovation, Regulatory, and Business Development, is transitioning to lead the potential carve-out of Elanco’s microbiome R&D platform","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000110465921122758/0001104659-21-122758-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioning"},{"label":"Role","value":"Executive Vice President of Innovation, Regulatory, and Business Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}